stockportfolio.pro
INCY vs MTD: Which Stock Is the Better Buy?
Incyte Corporation and Mettler-Toledo International Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — INCY vs MTD, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Incyte Corporation (INCY) | Mettler-Toledo International Inc. (MTD) | |
|---|---|---|
| Market cap | $23.4B | $26.5B |
| Revenue (latest FY) | $5.14B | $4.03B |
| Net income (latest FY) | $1.29B | $869.19M |
| Revenue growth (5y CAGR) | 14.0% | 5.5% |
| Net margin | 25.0% | 21.6% |
| Return on equity | 24.9% | -3677.4% |
| P/E ratio | 16.6 | 30.8 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 8 | 10 |
| Positive free cash flow | — | Yes |
See the full INCY vs MTD breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open INCY's full financials → Open MTD's full financials →More comparisons
Frequently asked questions
Which is bigger, INCY or MTD?
Mettler-Toledo International Inc. is larger by market capitalization — $26.5B versus $23.4B.
Which grows faster, INCY or MTD?
Over the last five fiscal years, Incyte Corporation grew revenue faster — 14.0%/yr versus 5.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.